The new business model of the biopharmaceutical industry that focuses on the unmet needs of smaller patient populations has diversified today’s pipelines and brought new hope to patient care. In its own pursuit to tackle rare diseases and improve the quality of life for patients in need, Kaleido Biosciences, a clinical-stage healthcare company, has focused its efforts on Microbiome Metabolic Therapies (MMT™) to help address a variety of diseases and conditions. Their lead candidate, KB195, is intended to treat urea cycle disorder (UCD), which affects a small population of patients who inherit this serious, rare, and life-threatening disease.1 To bring KB195 to patients, Kaleido needed an IND filed by the end of its first year. And as a small company, it lacked the resources to accomplish this on its own, so it had to consider an alternative yet efficient route to meet its aggressive timeline.
To meet an aggressive timeline with a lack of resources, Kaleido Biosciences had to consider an alternative yet efficient route.